183 related articles for article (PubMed ID: 30323891)
1. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer.
Elbaz M; Ahirwar D; Xiaoli Z; Zhou X; Lustberg M; Nasser MW; Shilo K; Ganju RK
Oncotarget; 2018 Sep; 9(71):33459-33470. PubMed ID: 30323891
[TBL] [Abstract][Full Text] [Related]
2. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents.
Nabissi M; Morelli MB; Santoni M; Santoni G
Carcinogenesis; 2013 Jan; 34(1):48-57. PubMed ID: 23079154
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer.
Marinelli O; Morelli MB; Annibali D; Aguzzi C; Zeppa L; Tuyaerts S; Amantini C; Amant F; Ferretti B; Maggi F; Santoni G; Nabissi M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751388
[TBL] [Abstract][Full Text] [Related]
4. Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway.
Lei S; Fan P; Wang M; Zhang C; Jiang Y; Huang S; Fang M; He Z; Wu A
Exp Ther Med; 2020 Aug; 20(2):1630-1636. PubMed ID: 32742395
[TBL] [Abstract][Full Text] [Related]
5. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
Morelli MB; Offidani M; Alesiani F; Discepoli G; Liberati S; Olivieri A; Santoni M; Santoni G; Leoni P; Nabissi M
Int J Cancer; 2014 Jun; 134(11):2534-46. PubMed ID: 24293211
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2.
Misri S; Kaul K; Mishra S; Charan M; Verma AK; Barr MP; Ahirwar DK; Ganju RK
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267489
[TBL] [Abstract][Full Text] [Related]
7. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
8. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer.
Saghaeidehkordi A; Chen S; Yang S; Kaur K
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34063098
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models.
Patel N; Kommineni N; Surapaneni SK; Kalvala A; Yaun X; Gebeyehu A; Arthur P; Duke LC; York SB; Bagde A; Meckes DG; Singh M
Int J Pharm; 2021 Sep; 607():120943. PubMed ID: 34324983
[TBL] [Abstract][Full Text] [Related]
11. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Shi Y; Bieerkehazhi S; Ma H
Int J Clin Exp Pathol; 2018; 11(5):2347-2355. PubMed ID: 31938346
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Insulin-Like Growth Factor Binding Protein-3 As a Biomarker in Triple-Negative Breast Cancer Xenograft Tumors: Effect of Targeted Therapy and Comparison With Chemotherapy.
Julovi SM; Martin JL; Baxter RC
Front Endocrinol (Lausanne); 2018; 9():120. PubMed ID: 29623068
[TBL] [Abstract][Full Text] [Related]
13. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
14. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
15. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
[TBL] [Abstract][Full Text] [Related]
16. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
[TBL] [Abstract][Full Text] [Related]
17. TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer.
Yamada T; Ueda T; Shibata Y; Ikegami Y; Saito M; Ishida Y; Ugawa S; Kohri K; Shimada S
Urology; 2010 Aug; 76(2):509.e1-7. PubMed ID: 20546877
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
19. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
